PXD062331

PXD062331 is an original dataset announced via ProteomeXchange.

Title	MECOM: A novel player in AR-driven Treatment Resistant Castration-Resistant Prostate Cancer
Description	Reprogramming of the androgen receptor (AR) cistrome is associated with disease progression, and advanced castrate-resistant prostate cancers (CRPC) tend to rely on a reprogrammed/non-canonical AR signaling that is addictive to AR signaling inhibitor (ARSI) resistance. We identified EVI1, an oncogenic nuclear transcription factor, EVI1 coded by MECOM, as a novel AR-recruited co-activator for non-canonical signaling. In prostate cancer, MECOM is exclusively overexpressed in CRPC and enzalutamide-resistant CRPC and interacts with AR in the nucleus. MECOM knockdown cells exhibited decreased proliferation, aberration of critical cell survival transcriptional programs, suppressed super-enhancer (SE) activity, and increased pro-apoptotic signatures. Intriguingly, MECOM overexpression is vulnerable to PARP inhibitors regardless of DDR or HRR gene mutation status. These insights uncover the mechanistic role of MECOM in AR reprogrammed cistrome for cell survival and its vulnerability. More importantly, this study suggests that MECOM overexpression may be another biomarker that could significantly broaden the use of PARP inhibitors beyond those with HRR gene mutations.
HostingRepository	PRIDE
AnnounceDate	2026-06-08
AnnouncementXML	Submission_2026-06-08_01:02:31.055.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Remi Adelaiye-Ogala
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606;
ModificationList	iodoacetamide derivatized residue
Instrument	6410 Triple Quadrupole LC/MS

Revision	Datetime	Status	ChangeLog Entry
0	2025-03-27 21:02:16	ID requested
⏵ 1	2026-06-08 01:02:31	announced

Gulla S, Sharma T, Gardner E, Li C, Purohit TA, Xue C, Colligan S, Shyam Sundar S, Yang B, Trostel SY, Capaldo B, Bard JE, Ogunbowale T, Jawadwala A, Ma M, Qu J, Karzai F, Pili R, Jarrard DF, Sowalsky AG, VanderWeele DJ, Adelaiye-Ogala R, MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer. Cancer Res, 86(9):2143-2160(2026) [pubmed]

10.1158/0008-5472.can-25-1720;

submitter keyword: MECOM, epigenetics, castration-resistance, drug resistance, PARPi,prostate cancers, enzalutamide-resistance, androgen receptor, EVI1-MDS1 complex, Non-canonical AR

Remi adelaiye-Ogala
contact affiliation	University at Buffalo
contact email	remiadel@buffalo.edu
lab head
Remi Adelaiye-Ogala
contact affiliation	University at Buffalo
contact email	remiadel@buffalo.edu
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/06/PXD062331

PRIDE project URI

• PRIDE
  1. PXD062331
     1. Label: PRIDE project
     2. Name: MECOM: A novel player in AR-driven Treatment Resistant Castration-Resistant Prostate Cancer